Opportunity ID: 231914

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-DA-14-004
Funding Opportunity Title:: Medications Development Centers of Excellence Cooperative Program (U54)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Education
Category Explanation::
Expected Number of Awards:: 2
CFDA Number(s):: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 1
Posted Date:: Apr 26, 2013
Last Updated Date::
Original Closing Date for Applications:: Aug 15, 2013
Current Closing Date for Applications:: Aug 15, 2013
Archive Date:: Sep 15, 2013
Estimated Total Program Funding:: $ 3,000,000
Award Ceiling:: $1,000,000
Award Floor:: $

Eligibility

Eligible Applicants:: Native American tribal governments (Federally recognized)
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name:: National Institutes of Health
Description:: This FOA solicits Specialized Center Cooperative Agreement (U54) applications to provide support for Medications Development Centers of Excellence (MDCE) with emphasis on clinical research directed towards the identification, evaluation, and development of safe and effective medications and biologics for treatment of substance use disorders (SUDs). Research may focus on both currently approved or novel, investigational products. Centers may have a translational component to reinforce rationale of medications for testing.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Related Documents